Cronos Group Inc (NASDAQ:CRON)’s share price was up 6.8% on Tuesday . The stock traded as high as $5.50 and last traded at $5.47, approximately 5,468,373 shares traded hands during trading. A decline of 39% from the average daily volume of 8,990,094 shares. The stock had previously closed at $5.12.
Several analysts have recently weighed in on CRON shares. BidaskClub upgraded shares of Cronos Group from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 18th. Zacks Investment Research raised shares of Cronos Group from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Tuesday, March 17th. ValuEngine raised shares of Cronos Group from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. MKM Partners raised shares of Cronos Group from a “neutral” rating to a “buy” rating and reduced their target price for the company from $12.00 to $11.00 in a report on Wednesday, March 4th. Finally, Raymond James set a $12.00 target price on shares of Cronos Group and gave the company an “outperform” rating in a report on Saturday, December 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.78.
The firm has a market cap of $1.79 billion, a P/E ratio of 6.47 and a beta of 3.03. The business’s fifty day simple moving average is $6.23 and its 200-day simple moving average is $7.65.
About Cronos Group (NASDAQ:CRON)
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ?MMPR?. The firm typically invests in companies based in Canada.
Read More: What are retained earnings?
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.